• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Omeros Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    6/12/24 4:48:20 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OMER alert in real time by email
    omer20240516_8k.htm
    false 0001285819 0001285819 2024-06-06 2024-06-06
     


     ​
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT
     ​
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     ​
    Date of Report (Date of earliest event reported): June 6, 2024

    OMEROS CORPORATION

    (Exact name of Registrant as Specified in Its Charter)
     ​
    Washington
    001-34475
    91-1663741
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
         
    201 Elliott Avenue West
    Seattle, WA
     
    98119
    (Address of Principal Executive Offices)
     
    (Zip Code)
     ​
    Registrant’s Telephone Number, Including Area Code: (206) 676-5000
     ​
    (Former Name or Former Address, if Changed Since Last Report)
     ​
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     ​
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ​
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ​
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ​
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     ​
    Securities Registered Pursuant to Section 12(b) of the Act:
     ​
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common stock, $0.01 par value per share
    OMER
    The Nasdaq Stock Market LLC
     ​
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
     ​
    Emerging growth company ☐
     ​
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     ​


     
     

     
     
    Item 5.02
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    Retirement of Executive Officer
     
    On June 10, 2024, Michael A. Jacobsen informed the Board of Directors of Omeros Corporation (“Omeros” or the “Company”) of his intention to retire from his positions as the Company’s Vice President, Finance, Chief Accounting Officer and Treasurer, effective June 30, 2024.  To facilitate an effective transition of his responsibilities and as part of a planned transition to retirement after 10 years with Omeros, Mr. Jacobsen will continue to serve as a part-time employee and senior finance advisor to the Company. In this role, Mr. Jacobsen will receive a cash payment of $5,000 per month and will be eligible to receive a ratable bonus based on his continued service to the Company. In addition, Mr. Jacobsen’s outstanding stock options will continue to vest during his continued service to the Company.
     
    Appointment of Executive Officer
     
    On June 10, 2024, the Company’s Board of Directors appointed David J. Borges as the Company’s Vice President, Finance, Chief Accounting Officer and Treasurer, effective June 30, 2024 (the “Effective Date”), and designated him as the Company’s principal financial officer and principal accounting officer as of the Effective Date. Mr. Borges, 60, joined Omeros in June 2020 as Senior Director, Financial Planning & Analysis and was promoted to Associate Vice President, Financial Planning &Analysis in April 2022. Prior to joining Omeros, Mr. Borges served as Vice President, Finance and Administration, at Bulletproof 360, Inc., a health and wellness company, where he directed and managed all aspects of corporate finance, accounting, information technology, human resources, facilities, and legal from October 2014 until October 2019. From May 2009 to June 2014, Mr. Borges served as Chief Financial Officer and Vice President of Advanced Refreshment LLC, a producer of private label bottled water and water-based beverages. From July 2001 to May 2009, Mr. Borges served as Finance and Business Integration Director at Merck & Co., Inc. (“Merck”), a biopharmaceutical company, after Merck acquired Rosetta Inpharmatics, where Mr. Borges had been serving as Director of Finance & Administration/Controller since 1998. Mr. Borges is a certified public accountant and received his B.S. in Commerce in Accounting from Santa Clara University.
     
    Mr. Borges is eligible to participate in Omeros' compensation and benefits programs on terms consistent with other eligible employees. Mr. Borges' base salary is $325,000 per annum. His target bonus for the 2024 performance period under the Company's annual bonus program is 35% of his annual salary. Mr. Borges is also eligible to receive, at the discretion of the Board of Directors or the Compensation Committee thereof, stock option or other equity awards under the terms of the Omeros Corporation 2017 Omnibus Incentive Compensation Plan (as amended, the “2017 Plan”). The 2017 Plan was previously filed as Exhibit 10.1 to Omeros’ Current Report on Form 8-K filed on June 28, 2023. Mr. Borges and the Company also entered into a standard indemnification agreement for officers and directors, the form of which previously was filed as Exhibit 10.1 to Omeros’ Registration Statement on Form S-1 filed on January 9, 2008.
     
    Mr. Borges is not party to any understanding or arrangement in connection with his appointment as an executive officer and has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.
     
     

     
     
     
    Item 5.07
    Submission of Matters to a Vote of Security Holders.
     
    Omeros held its 2024 Annual Meeting of Shareholders on June 6, 2024 (the “Annual Meeting”). Shareholders of record at the close of business on April 18, 2024 were entitled to vote 57,944,159 shares of common stock at the Annual Meeting. A total of 43,954,766 shares (75.86%) were represented at the Annual Meeting in person or by proxy. Set forth below is a brief description of each matter voted upon at the Annual Meeting and the final voting results for each matter.
     
    (1)
    The following individuals were elected to serve as directors by the vote set forth below. Thomas F. Bumol, Ph.D., Gregory A. Demopulos, M.D. and Leroy E. Hood, M.D., Ph.D were elected as Class III directors, each to serve until the 2027 Annual Meeting of Shareholders, or, in each case, until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
     ​
    ​
    ​
    For
    ​
    Against
    ​
    Abstain
    ​
    Broker Non-Votes
    Thomas F. Bumol, Ph.D.
    ​
    20,956,471
    ​
    2,232,496
    ​
    106,567
    ​
    20,659,232
    Gregory A. Demopulos, M.D.
    ​
    21,111,759
    ​
    2,071,701
    ​
    112,074
    ​
    20,659,232
    Leroy E. Hood, M.D., Ph.D.
    ​
    18,924,100
    ​
    4,263,548
    ​
    107,886
    ​
    20,659,232
     ​
     ​
    (2)
    Shareholders approved an advisory resolution regarding the compensation of Omeros’ named executive officers as reported in the proxy statement for the 2024 Annual Meeting of Shareholders by the vote set forth below.
     ​
    For
    ​
    Against
    ​
    Abstain
    ​
    Broker Non-Votes
    15,849,545
    ​
    6,977,695
    ​
    468,294
    ​
    20,659,232
     ​
     
    (3)
    Shareholders ratified the appointment of Ernst & Young LLP as Omeros’ independent registered public accounting firm for the fiscal year ending December 31, 2024 by the vote set forth below.
     ​
    For
    ​
    Against
    ​
    Abstain
    ​
    Broker Non-Votes
    41,807,973
    ​
    1,682,263
    ​
    464,530
    ​
    —
     
     ​
    ​
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    ​
    OMEROS CORPORATION
    ​
    ​
    ​
    Date: June 12, 2023
    By:
    /s/ Gregory A. Demopulos
    ​
    ​
    Gregory A. Demopulos, M.D.
    ​
    ​
    President, Chief Executive Officer and
    ​
    ​
    Chairman of the Board of Directors
     ​
     
    Get the next $OMER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMER

    DatePrice TargetRatingAnalyst
    6/10/2025$9.00Buy
    H.C. Wainwright
    12/23/2024$36.00Buy
    D. Boral Capital
    11/14/2024$9.00Buy
    Rodman & Renshaw
    12/8/2022$12.00 → $2.00Buy → Neutral
    UBS
    11/8/2022$8.00 → $3.00Neutral → Underperform
    BofA Securities
    6/8/2022$12.00 → $4.00Buy → Neutral
    BofA Securities
    10/19/2021$19.00 → $12.00Buy
    HC Wainwright & Co.
    10/8/2021Neutral → Underweight
    JP Morgan
    More analyst ratings

    $OMER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

    – Permanent, product-specific J-code facilitates efficient claims and reimbursement – Omeros Corporation (NASDAQ:OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026. "For patients with TA-TMA, access to effective treatment without unnecessary delay is critical," said Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer of Omeros. "

    4/16/26 8:45:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

    – Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth

    3/31/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

    Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Inves

    3/26/26 8:45:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    SEC Filings

    View All

    SEC Form 10-K filed by Omeros Corporation

    10-K - OMEROS CORP (0001285819) (Filer)

    3/31/26 4:06:16 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OMEROS CORP (0001285819) (Filer)

    3/31/26 4:05:19 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Omeros Corporation

    SCHEDULE 13G/A - OMEROS CORP (0001285819) (Subject)

    3/27/26 11:04:36 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $OMER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $OMER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Demopulos Gregory A Md bought $25,200 worth of shares (15,000 units at $1.68) (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/21/23 8:11:35 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Demopulos Peter A Md bought $15,300 worth of shares (10,000 units at $1.53), increasing direct ownership by 5% to 208,516 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    11/17/23 9:46:20 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Omeros with a new price target

    H.C. Wainwright initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    6/10/25 8:09:22 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Omeros with a new price target

    D. Boral Capital initiated coverage of Omeros with a rating of Buy and set a new price target of $36.00

    12/23/24 7:27:28 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Omeros with a new price target

    Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    11/14/24 7:47:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, CEO & President Demopulos Gregory A Md exercised 400,000 shares at a strike of $10.27 and covered exercise/tax liability with 357,678 shares, increasing direct ownership by 3% to 1,469,308 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    2/20/26 9:40:28 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Finance & CAO Borges David J. sold $750,915 worth of shares (60,000 units at $12.52) and exercised 30,000 shares at a strike of $3.06, closing all direct ownership in the company (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    1/14/26 5:25:24 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, CEO & President Demopulos Gregory A Md gifted 600,000 shares and received a gift of 600,000 shares, decreasing direct ownership by 30% to 1,426,986 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    10/15/25 7:16:04 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Financials

    Live finance-specific insights

    View All

    Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

    – Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth

    3/31/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

    Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Inves

    3/26/26 8:45:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    3/27/24 2:47:02 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

    SC 13G/A - OMEROS CORP (0001285819) (Subject)

    2/14/24 6:05:17 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Omeros Corporation

    SC 13G - OMEROS CORP (0001285819) (Subject)

    2/13/24 5:12:07 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OMER
    Leadership Updates

    Live Leadership Updates

    View All

    Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

    Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch

    10/19/23 8:30:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care